PDCD1 and esophageal adenocarcinoma: The CheckMate 649 trial demonstrated that the PD-1 inhibitor combined with chemotherapy had better OS, PFS benefits, and an acceptable safety profile compared to chemotherapy alone in previously untreated patients with advanced gastric, gastro-esophageal junction, or esophageal adenocarcinoma.